Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Glucarpidase

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    M8, signs an exclusive agreement with SERB to bring Voraxaze to Latin America
    M8, signs an exclusive agreement with SERB to bring Voraxaze to Latin America

    20 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/m8-pharmaceuticals-an-acino-company-signs-an-exclusive-agreement-with-serb-pharmaceuticals-to-bring-voraxaze-glucarpidase-to-latin-america-302093643.html

    PR NEWSWIRE
    20 Mar 2024
    Share Share
    NCCN Issues Guideline Update on the Use of High-Dose Methotrexate, Glucarpidase
    NCCN Issues Guideline Update on the Use of High-Dose Methotrexate, Glucarpidase

    07 Jul 2023

    // ONCLIVE

    https://www.onclive.com/view/nccn-issues-guideline-update-on-the-use-of-high-dose-methotrexate-glucarpidase-in-all-b-cell-lymphoma

    ONCLIVE
    07 Jul 2023
    Share Share
    SERB SAS' Voraxaze (glucarpidase) Receives Approval in Europe
    SERB SAS' Voraxaze (glucarpidase) Receives Approval in Europe

    20 Jan 2022

    // EMA

    https://www.ema.europa.eu/en/medicines/human/EPAR/voraxaze-0

    EMA
    20 Jan 2022
    Share Share
    SERB receives positive CHMP opinion for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity
    SERB receives positive CHMP opinion for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity

    25 Nov 2021

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/serb-receives-positive-chmp-opinion-for-voraxaze-glucarpidase-as-rescue-therapy-for-high-dose-methotrexate-toxicity-1639817595.pdf

    PRESS RELEASE
    25 Nov 2021
    Share Share
    Initial study results show feasibility of outpatient methotrexate administration
    Initial study results show feasibility of outpatient methotrexate administration

    12 Nov 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/initial-study-results-show-feasibility-of-outpatient-methotrexate-administration-with-planned-use-voraxaze-glucarpidase-during-covid-19-pandemic-301171687.html

    PRNEWSWIRE
    12 Nov 2020
    Share Share
    BTG Specialty Pharmaceuticals announces the European Medicines Agency
    BTG Specialty Pharmaceuticals announces the European Medicines Agency

    17 Aug 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/btg-specialty-pharmaceuticals-announces-the-european-medicines-agency-has-accepted-for-review-a-marketing-authorisation-application-for-voraxaze-301113141.html

    PRNEWSWIRE
    17 Aug 2020
    Share Share